triple agonist: the version I wish someone had shown me in week 1
triple agonist: the version I wish someone had shown me in week 1. Numbers below. Ask me the boring questions, they are the useful ones. It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.…
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
the TRIUMPH programme is still running, so anything definitive is premature
not approved anywhere, which is the single most important fact in this board
the phase 2 numbers were striking and they were also 48 weeks in a small population
wait for phase 3 before you argue about rankings
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.